| All patients (n = 30) | Castrate-resistant (n = 11) | Castrate-sensitive (n = 19) | p-value |
---|---|---|---|---|
Biochemical/clinical failure | 16 (53%) | 10 (91%) | 6 (32%) | 0.008 |
Metastatic progression | 10 (63%) | 7 (64%) | 3 (16%) | 0.007 |
Median time to failure, months (range) | 16 (6–38) | 13 (6–28) | 23 (10–38) |  |
Median RFS, months (range) | 22 (6–43) | 13 (6–28) | 26 (10–43) |  < 0.001 |
2 and 3-year RFS | 60% and 53% | 18% and 9% | 84% and 79% |  < 0.001 |
2 and 3-year MFS | Â | 36% and 27% | 90% and 90% | 0.001 |